Pharmacyclics (PCYC +8.5%) soars as positive data is released on its phase II study of the...

|By:, SA News Editor

Pharmacyclics (PCYC +8.5%) soars as positive data is released on its phase II study of the potential blockbuster Btk inhibitor. The stock's a blockbuster itself, up nearly 60% since hitting a 52-week low in early March.